BPC-157 Dosage Guide

BPC-157 is a 15-amino acid peptide chain that has demonstrated remarkable regenerative properties in preclinical studies. Originally isolated from human gastric juice, this stable gastric pentadecapeptide has shown cytoprotective and wound-healing effects across multiple organ systems in animal models.

Research published in Journal of Physiology and related publications has documented BPC-157's ability to accelerate tendon, ligament, muscle, and gut healing in rodent studies. It operates through multiple mechanisms including upregulation of growth factor expression, nitric oxide modulation, and angiogenesis promotion. All research with BPC-157 is for investigational purposes only.

Dosage protocols in the research literature vary based on the study model and route of administration. The following table summarizes commonly referenced dose ranges:

Most rodent studies use a dose equivalent to approximately 10 mcg/kg body weight administered systemically. Researchers typically start at the lower end to assess tolerance before escalating.

BPC-157 is typically administered once or twice daily via subcutaneous injection. For injury-focused research protocols, injection near the site of interest is commonly employed. When using a twice-daily protocol, doses are typically spaced 12 hours apart — for example, morning and evening.

Cycling: Common cycling protocols include 4 weeks on / 2 weeks off, or continuous use for up to 12 weeks followed by a 4-week break. BPC-157 does not appear to exhibit tachyphylaxis in animal studies, but periodic breaks are recommended as a precaution.

BPC-157 is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water (BAC water) before use.

• Step 1: Clean the rubber stopper of the BPC-157 vial and BAC water vial with an alcohol swab.
• Step 2: Draw the desired amount of BAC water into a syringe. For a 5 mg vial, adding 2 mL of BAC water yields 2,500 mcg/mL (each 0.1 mL = 250 mcg).
• Step 3: Inject the BAC water slowly into the vial, aiming the stream against the glass wall — never directly onto the powder.
• Step 4: Gently swirl until dissolved. Do not shake.
• Step 5: Store reconstituted solution refrigerated at 2–8°C. Use within 28 days.

Administer via subcutaneous injection using an insulin syringe (29–31 gauge). Inject into the abdominal fat pad or near the area of interest.

BPC-157 has demonstrated a favorable safety profile in animal studies with no reported LD50 (lethal dose) established in rodent models, suggesting a wide therapeutic window.

• Low doses (200–250 mcg/day): Minimal reported side effects. Occasional injection site redness.
• Moderate doses (250–500 mcg/day): Some reports of mild nausea, dizziness, or headache.
• Higher doses (500+ mcg/day): Increased likelihood of digestive discomfort. Theoretical concerns about growth factor stimulation in subjects with pre-existing conditions.

This compound is intended for research purposes only and is not approved by the FDA for human use. No human clinical trials have established the safety or efficacy of BPC-157.

Always consult a qualified healthcare provider before beginning any research protocol. Individuals with active cancers or a history of malignancy should exercise extreme caution due to BPC-157's pro-angiogenic properties. Do not use if pregnant or breastfeeding.